# | Title | Journal | Year | Citations |
---|
1 | Mutations driving CLL and their evolution in progression and relapse | Nature | 2015 | 868 |
2 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial | Lancet Haematology,the | 2016 | 442 |
3 | Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial | Blood | 2014 | 428 |
4 | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial | Lancet Haematology,the | 2017 | 258 |
5 | Recurrent mutations refine prognosis in chronic lymphocytic leukemia | Leukemia | 2015 | 253 |
6 | Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia | Blood | 2014 | 244 |
7 | Precision oncology for acute myeloid leukemia using a knowledge bank approach | Nature Genetics | 2017 | 229 |
8 | Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial | Lancet Oncology, The | 2017 | 219 |
9 | Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome | Blood | 2013 | 208 |
10 | Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy | Blood | 2014 | 204 |
11 | Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group | Hematological Oncology | 1984 | 198 |
12 | High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations | Blood | 2012 | 179 |
13 | ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation | Leukemia | 2018 | 149 |
14 | Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia | Haematologica | 2019 | 144 |
15 | Requirement for CDK6 in MLL-rearranged acute myeloid leukemia | Blood | 2014 | 139 |
16 | Mutual exacerbation of peroxisome proliferator‐activated receptor γ coactivator 1α deregulation and α‐synuclein oligomerization | Annals of Neurology | 2015 | 112 |
17 | Comparative analysis of KRAS codon 12, 13, 18, 61 and 117 mutations using human MCF10A isogenic cell lines | Scientific Reports | 2015 | 111 |
18 | Venetoclax and obinutuzumab in chronic lymphocytic leukemia | Blood | 2017 | 108 |
19 | Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study | Journal of Clinical Oncology | 2021 | 74 |
20 | Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL | Blood | 2021 | 72 |
21 | Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia | Leukemia | 2016 | 69 |
22 | NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG | Blood | 2013 | 68 |
23 | Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia | Leukemia | 2014 | 64 |
24 | Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33 | Journal of Experimental Medicine | 2012 | 63 |
25 | Analysis of 11q22–q23 deletion target genes in B-cell chronic lymphocytic leukaemia: Evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B | European Journal of Cancer | 2007 | 62 |
26 | Unified classification and risk-stratification in Acute Myeloid Leukemia | Nature Communications | 2022 | 61 |
27 | From Biology to Therapy: The CLL Success Story | HemaSphere | 2019 | 55 |
28 | Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials | Leukemia | 2021 | 55 |
29 | Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders | Brain, Behavior, and Immunity | 2009 | 53 |
30 | Molecular map of chronic lymphocytic leukemia and its impact on outcome | Nature Genetics | 2022 | 52 |
31 | CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B | European Journal of Immunology | 2010 | 51 |
32 | RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia | Leukemia | 2018 | 51 |
33 | IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia | Blood | 2019 | 51 |
34 | CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling | Journal of Clinical Investigation | 2013 | 47 |
35 | Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial | Leukemia | 2022 | 47 |
36 | Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia | Leukemia Research | 2015 | 46 |
37 | KIT mutations confer a distinct gene expression signature in core binding factor leukaemia | British Journal of Haematology | 2010 | 44 |
38 | Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) | Haematologica | 2020 | 44 |
39 | Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia | Haematologica | 2015 | 42 |
40 | Discovery of Candidate DNA Methylation Cancer Driver Genes | Cancer Discovery | 2021 | 42 |
41 | The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia | Blood | 2022 | 40 |
42 | HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy | Haematologica | 2013 | 39 |
43 | Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia | Nature Communications | 2017 | 39 |
44 | The Differential Diagnosis and Treatment of Thrombotic Microangiopathies | Deutsches Ärzteblatt International | 2018 | 39 |
45 | Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group | Leukemia | 2017 | 38 |
46 | CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia | Leukemia | 2019 | 38 |
47 | A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial | Blood | 2021 | 36 |
48 | Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 | Haematologica | 2020 | 31 |
49 | Telomere shortening leads to earlier age of onset in ALS mice | Aging | 2016 | 31 |
50 | Prognostic markers and standard management of chronic lymphocytic leukemia | Hematology American Society of Hematology Education Program | 2015 | 29 |